JPMorgan Downgrades Vir Biotechnology (VIR) to Underweight Unfavorable Risk/Reward
Tweet Send to a Friend
(Updated - January 27, 2021 7:53 AM EST)JPMorgan analyst Anupam Rama downgraded Vir Biotechnology (NASDAQ: VIR) from Neutral to Underweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
